Aurora Cannabis (TSX:ACB) and Canopy Growth (TSX:WEED) Continue to Destroy Investor Wealth

The last month was really bad for cannabis investors, to say the least. Just when you thought that the cannabis stocks have bottomed out, the decline has gotten more severe. Horizons Marijuana Life Sciences Index ETF is trading at $11.47 and hit its 52-week low yesterday. The ETF fell 3.1% yesterday and is trading just above its IPO price of…

Read More

Should You Invest in Marijuana Stock IPOs?

Almost no industry has seen more IPOs in recent years than marijuana. Although big tech IPOs like Shopify have gotten the most attention, marijuana IPOs have been, by far, the most numerous on the TSX. In the past five years, at least half a dozen weed producers have gone public, with many more having plans to do so in the near…

Read More

Better Buy: Lightspeed (TSX:LSPD) vs. Aurora Cannabis (TSX:ACB)

Cannabis stocks have become a go-to choice for Canadian investors seeking market-beating returns. With stocks like Aurora Cannabis (TSX:ACB)(NYSE:ACB) having risen over 1,000% since their IPOs, they’ve made many investors wealthy. However, as anyone who bought marijuana stocks this summer will tell you, they come with a downside: volatility. While it’s possible to make money in marijuana bull markets, you can…

Read More

Marijuana Stock Investors: Don’t Miss Out on This IPO

Would the initial public offering of Breath of Life International be the most explosive IPO when the company finally lists on the TSX? Israel’s largest medical cannabis producer is known more as BOL Pharma in its home country. You shouldn’t miss on out on this marijuana IPO, as the company could be the global leader in medical cannabis. As of…

Read More

Tilray (NASDAQ:TLRY): The Fall of a Weed Stock

Remember Tilray (NASDAQ:TLRY)? During last summer’s weed bubble, it was one of the most talked about marijuana producers. Rising 755% from its IPO price in just two months, TLRY gained more than any other weed stock in the same period. At the time, investors were positively euphoric about the company’s elite VC backing and access to U.S. distribution networks, both of…

Read More

Investors: Hers’s Why Aphria (TSX:APHA) Is a Solid Long-Term Pick

Shares of Aphria (TSX:APHA)(NYSE:APHA) have made a strong comeback recently. The stock has gained 25% since the start of August 2019. While Aphria shares have fallen 60% since September last year, they are up by an impressive 1,050% since its IPO in December 2014. Most cannabis stocks have generated significant returns in the last five years, despite a steep pullback…

Read More

Is Cronos (TSX:CRON) Attractive After a Recent Pullback?

Cannabis investors have had a rough ride in the last 12 months. Several stocks lost significant value due to regulatory issues and missing analyst target estimates. Cannabis stocks were overvalued and expensive. Shares of Cronos Group (TSX:CRON)(NASDAQ:CRON) have fallen 46% since March 2019. Despite the recent pullback, the stock has returned a mind-blowing 1,825% since its IPO back in December…

Read More

“Low-Risk” Investors: 2 New Routes to Cannabis Exposure

There are several trains of thought when it comes to cannabis investing at the moment. While the serious capital gains enjoyed by traders in 2018 seem to have been consigned to recent history, investors are now eyeing stocks that could cash in on the coming legalization of edibles and other peripheral marijuana products this fall. Another set of investors are…

Read More

3 Marijuana IPOs That Could Make You Rich

Industry giant Canopy Growth had a sterling IPO back on April 4, 2014, when the shares of the company began trading on the Toronto’s Venture Exchange (TSXV). On the first day, the stock closed at $2.59. The hype over marijuana was not as puffed up as it is today. On October 15, 2017, or two days before the Cannabis Act became…

Read More

It’s IPO-Like: CannTrust Holdings (TSX:TRST) Could Triple or Fall to $0 … Should You Place Such a Bet?

Speculating on cannabis stocks isn’t for the faint of heart. If you’re not used to double-digit moves in either direction, you could seriously get hurt by following the herd. Moreover, it’s tough to form a sound investment thesis with the haze of uncertainty clouding the industry and the number of firms that have broken the rules set forth by Health…

Read More